parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.13 (overall 0.09)	0.13
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in megakaryocyte progenitors	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 3079

MED12L in astrocytes, braak-0.34 (p 0.378) → -0.26 (p 0.493)receipt 3086
MED12L in dopamine neurons, braak+0.29 (p 0.443) → +0.15 (p 0.697)receipt 3087

receipt 3087: MED12L in dopamine neurons, braak

power: full sample +0.09 (p 0.715, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.794, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.07 (p 0.781, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.21, sign flips 3; without severely affected donors +0.09 (p 0.715, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MED12L in dopamine neurons.

case closed: nothing better to follow up.

receipt 3086: MED12L in astrocytes, braak

power: full sample -0.28 (p 0.258, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.35 (p 0.150, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.34 (p 0.164, n 18). could be the mix.
skeptic: leave-one-out range -0.47 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.258, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MED12L in astrocytes.

case closed: nothing better to follow up.

loading the receipts